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Neurodegenerative diseasesHuntington's disease (HD) is characterized by brain atrophy. Localized atrophy of a speciﬁc structure could
potentially be a more sensitive biomarker reﬂecting neuropathologic changes rather than global volume
variation. We examined 90 TRACK-HD participants of which 30 were premanifest HD, 30 were manifest HD
and 30 were controls. Using FMRIB's Integrated Registration and Segmentation Tool, segmentations were
obtained for the pallidum, caudate nucleus, putamen, thalamus, accumbens nucleus, amygdala, and
hippocampus and overall volumes were calculated. A point distribution model of each structure was
obtained using Growing and Adaptive Meshes. Permutation testing between groups was performed to detect
local displacement in shape between groups. In premanifest HD overall volume loss occurred in the putamen,
accumbens and caudate nucleus. Overall volume reductions in manifest HD were found in all subcortical
structures, except the amygdala, as compared to controls. In premanifest HD shape analysis showed small
areas of displacement in the putamen, pallidum, accumbens and caudate nucleus. When the premanifest
group was split into two groups according to predicted disease onset, the premanifest HD group close to
expected disease onset showed more pronounced displacements in caudate nucleus and putamen compared
to premanifest HD far from disease onset or the total premanifest group. Analysis of shape in manifest HD
showedwidespread shape differences, most prominently in the caudal part of the accumbens nucleus, body of
the caudate nucleus, putamen and dorsal part of the pallidum. We conclude that shape analysis provides new
insights in localized intrastructural atrophy patterns in HD, but can also potentially serve as speciﬁc target
areas for disease tracking.gy, Leiden University Medical
s. Tel.: +31 71 526 5442, +31
. van den Bogaard).
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Huntington's disease is a slowly progressive neurodegenerative
genetic disease that affects the brain. Disease onset occurs typically
between the age of 35 and 45 years, with clinical symptoms in motor,
cognitive and behavior domains. Since the discovery of the genetic
defect on chromosome 4, the gene status of at-risk individuals can be
determined,making identiﬁcationof premanifest gene carriers possible.
This makes examination of brain structures possible in this symptom
free period, and can provide insight into pathophysiological changes
underlying the disease.
Currently,many studies focus onﬁnding reliablemarkers tomonitor
disease progression [1,2]. MRI measures show great potential of
becoming sensitive biomarkers for HD, as they are objective and havebeen applied to demonstrate abnormalities of both gray and white
matter structures [3]. Changes in basal ganglia are of special interest as
these structures display overall volume reduction in the premanifest
stages of HD. The caudate nucleus and putamen are reported to be
atrophied up to a decade before disease onset [1,2,4].
Two pathologic studies report on localized loss of neurons within a
structure, namely within the medial paraventricular portions of the
caudate nucleus, in the tail of the caudate nucleus, and in the dorsal
part of the putamen in a dorsal ventral manner [5,6]. Currently, in vivo
measures of atrophy have predominantly reported overall volumetric
change of a structure, representing a generalized loss of neurons and
axons. Unrepresented in this approach is localized loss of neurons, or
any other remodeling effects, which go unnoticed if these local
changes do not signiﬁcantly affect the total volume of the structure.
To examine how subcortical nuclei change locally, we have chosen
an automatedMRI analysis set-upusing FMRIB's IntegratedRegistration
and Segmentation Tool (FIRST) and the Growing and Adaptive Meshes
(GAMEs) tools. This approach is chosen because in this waywe obtain a
per participant individual segmentation and outer surface of several
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Voxel Based Morphometry (VBM) where a voxel wise comparison is
made between groups, also in this way we avoid some known
methodological issues associated with VBM [7,8].
The TRACK-HD study is a biomarker study [1], dedicated to ﬁnding
objective and sensitive measures for disease progression. This study
allows examination of a well deﬁned cohort of premanifest gene
carriers, manifest HD and controls. The aim of our study is to determine
how the subcortical nuclei locally change in shape in the premanifest
and the manifest stage of HD in relation to global volumetric changes.
2. Methods
2.1. Subjects
Themulticentre Track-HD cohort consists in total of 366 participants.
All of the 90participants enrolled at the LeidenUniversityMedical Centre
from the TRACK-HD cohort were included for this analysis (premanifest
HD n=30, manifest HD n=30, control n=30). Inclusion criteria for the
premanifest group consisted of a CAG-repeat length ≥40, absence of
motor disturbances on the Uniﬁed Huntington's Disease Rating Scale
(UHDRS) deﬁned as a total motor score (TMS) b5. The UHDRS TMS is a
clinical rating of the amount of motor disturbances, grading several
distinct motor features separately such as chorea, dystonia, rigidity,
bradykinesia and eye movements, resulting in a sum score ranging from
0 to 124. Additionally a disease burden score of≥250 was mandatory to
ensure that the premanifest group was within 16 years of the predicted
age of onset [9,10]. For an additional analysis within the premanifest
group, a further subdivision of the group was performed on the basis of
themedian predicted years to diagnosis into premanifest A (10.8 ormore
years to disease onset, N=16) and premanifest B (closer than 10.8 years
to disease onset, N=14) based on Langbehn's et al. survival analysis
formula [10,11] identical to previous reports from the TRACK-HD study
[1,12]. Inclusion criteria for the manifest HD group consisted of a CAG
repeat≥40, a TMS≥5 and a Total Functional Capacity (TFC)≥7. The TFC
is a clinical scale assessing the activities in daily life (range 0–13) such as
job capability, ﬁnances, daily chores and self care. Healthy gene negative
family members or partners/spouses were included as controls.
Exclusion criteria consisted of any signiﬁcant (neurological) comorbidity,
history of severe head trauma, a major psychiatric diagnosis and MRI
incompatibility. Themedical ethical committee approved the study, andFig. 1. Processing pipeline from MRI acqwritten informed consent was obtained from all participants. Detailed
description of recruitment and inclusion criteria is given in the TRACK-
HD baseline paper [1].
2.2. MRI acquisition
In accordance with the TRACK-HD protocol, all participants under-
went MRI scanning on a 3 Tesla Philips whole body scanner (Philips
Medical Systems, Best, The Netherlands) with an eight channel receive
and transmit coil array. T1-weighted image volumes were acquired
using a 3D MPRAGE acquisition sequence with the following imaging
parameters: TR=7.7 ms, TE=3.5 ms, FA=8°, FOV=24 cm, matrix
size 224×224×164 with sagittal slices to cover the entire brain with a
slice thickness of 1.0 mm with no gap between slices, total acquisition
time was ~9 min.
2.3. Post-processing and statistics
The analysis pipeline is depicted in Fig. 1.
2.3.1. Overall volume analysis
Using FMRIB's Integrated Registration and Segmentation Tool
(FIRST), subcortical nuclei were afﬁne registered to MNI152 standard
space using linear registration and subsequently automatically
segmented [13,14]. Volumes for pallidum, caudate nucleus, putamen,
thalamus, accumbens nucleus, amygdala, and the hippocampus were
calculated. Analysis of variance was performed, correcting for age,
gender and intracranial volume (ICV).
The rationale to use FSL FIRST as our registration and segmentation
tool was the fact that the tool has an automated set-up and is therefore
an unbiased approach. The validity of the tool to register and segment
with great accuracy is described by Patenaude et al. [13–15].
Furthermore the automated set-up makes it relatively easy to use in
large cohorts. A previous study showed the reliable use of this tool inHD
for volumetric analysis in HD [12]. This tool has been and is currently
being used in many other studies regarding different neurological
disorders, among others Alzheimer's Disease [16]. FSL FIRST has been
compared to another automated segmentation tool, namely Freesurfer,
with comparison to manual segmentation. It was concluded that
Freesurfer provided better results for the hippocampus and FIRST for
the amygdala in terms of segmentation and shape analysis. However,uisition to Hotelling's T2 statistics.
Table 1
Group characteristics.
Control
(mean±SD)
Premanifest HD
(mean±SD)
Manifest HD
(mean±SD)
Age 48.6±8.3 43.3±8.0 47.6±10.3
CAG n.e. 42.5±2.4 43.6±2.6
Years to onset n.a. 11.6±4.3 n.a.
UHDRS TMS 2.6±2.4 2.5±1.4 21.9±11.1 *
TFC 13.0±0.2 12.6±0.8 10.4±2.0 *
Gender (N ♀/♂) 16/14 18/12 21/9
Demographic variables of the three groups. CAG=Cytosine-Adenosine-Guanine
repeat. UHDRS=Uniﬁed Huntington's Disease Rating Scale Total Motor Score,
TFC=Total Functional Capacity. n.a.=not applicable, n.e=not examined.
*=signiﬁcant different from the control and premanifest HD group with pb0.05.
Table 2
Volumes of subcortical nuclei.
Control Premanifest HD Manifest HD
Mean volume SD Mean volume SD Mean volume SD
Accumbens nucleus
Right 444 135 369 * 107 356 * 184
Left 605 136 544 * 112 381 ** 140
Amygdala
Right 1344 191 1376 312 1251 307
Left 1216 316 1218 381 1084 343
Caudate nucleus
Right 3339 504 2922 * 430 2450 ** 447
Left 3207 399 2848 * 493 2283 ** 394
Hippocampus
Right 3855 658 3820 664 3132 ** 671
Left 3660 570 3390 * 510 3121 ** 478
Pallidum
Right 1528 278 1443 326 1025 ** 319
Left 1648 348 1524 331 1071 ** 333
Putamen
Right 4597 692 4078 * 690 3283 ** 463
Left 4664 742 4176 * 607 3255 ** 511
Thalamus
Right 7424 605 7432 730 6795 * 806
Left 7328 840 7260 894 6782 * 794
Volumetric analysis of seven structures. Means are the absolute measured values
(mm3). Signiﬁcance is after correction for intracranial volume, gender and age.
* signiﬁcant difference from controls pb0.05.
* * signiﬁcant difference from controls pb0.001.
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segmentation, where no signiﬁcant difference was found for the
amygdala volume manual versus FIRST segmentation [17]. FIRST
performed better in the smaller subcortical structures in a scan–rescan
study [18], and since TRACK-HD is set-up as a longitudinal study this is
the logical choice considering all of the above arguments. However, it
must be noted that all these methodological studies make use of a
healthy control group, and to our knowledgeno study comparing expert
manual tracing versus automated segmentation in diseased/atrophied
states exists.
Additional quality control was performed via a visual inspection of
all the segmentations using the original T1-weighted scans and
projecting the individual segmentations on top of these images. Special
attention was given to the outliers in terms of volume. Several
registration errors resulted in erroneous segmentations and subse-
quently these scans were re-run until satisfactory segmentations were
acquired.No signiﬁcantmismatcheswere visually seenafter these steps.
2.3.2. Shape analysis
To perform shape analysis, comparative meshes for each structure
were built. For this purpose theGrowing andAdaptiveMeshes (GAMEs)
algorithm was utilized [19], making use of the segmentations acquired
from FIRST. GAMEs has been previously successfully applied for
analyzing shape variations in Alzheimer's disease [20,21]. This algo-
rithm builds a deformable surface mesh model based on an average of
the 30 control group segmentations. This general mesh model consists
of numerous nodes which are equal in number for all meshes used for
the comparative analysis across groups. Using thesemeshes, local shape
analysis was performed by repeated permutation tests via a Hotelling's
T2 statistical test. The following procedure was applied: a subsampling
process was performed, with random samples taken from the control
and the HD groups; subsequently, permutation tests (based on 10.000
iterations, in order to allow for p-values as lowas10−4)were performed
to detect signiﬁcant different location between groups, at a conﬁdence
level of 99%. In total 25 sub-sampling iterations were performed, each
sub-sample containing a minimum of 60% of the entire group
population. For each node the signiﬁcance level was assessed for all
structures analyzed. The latter step is to ensure that the ﬁndings are not
due to outliers in either the control or the HD group. True ﬁndings
appear in themajority of the subsample analyses, which can be deﬁned
as either 80 or 95% of the subsamples depending on the desired
statistical scrutiny. Graphical display does not only show the area of the
surface affected in 80–95% of the sub-sampling, but also the amount of
displacement in millimeters. We have chosen to use the most
conservative option, namely the 95% level; thus the signiﬁcant locations
are at an α=0.01, 95% of the times in which the sub-sampling was
performed. Three groups were included in the analysis, and the
comparisons are displayed for the premanifest group versus the control
group and secondly themanifest HD group versus the control group. An
additional analysis was performed in an identical manner with the
premanifest A and premanifest B groups both compared to the control
group. The rationale to perform this additional analysis lies in the fact
that there were only limited ﬁndings in the premanifest group, which
could be due to the fact of a heterogenous premanifest group in terms of
predicted years to disease onset. This was addressed by the subdivision
of the premanifest group according to predicted disease onset as
described above; however noted was the potential disadvantage of loss
of statistical power.
3. Results
3.1. Demographic characteristics of the study groups
The clinical features of the three groups are shown in Table 1.
There were no statistically signiﬁcant differences between the control
and premanifest group. The UHDRS total motor score and totalfunctional capacity were different between the manifest and control
or premanifest group.3.2. Volumetric analysis
Signiﬁcant differences in overall volumes between the premanifest
and control group were apparent in the accumbens nucleus, caudate
nucleus, left hippocampus and putamen. In the manifest HD group all
volumes were signiﬁcantly reduced as compared to controls, except
for the amygdala. The overall volumes are shown in Table 2.3.3. Shape analysis
The shape analysis for the basal ganglia structures accumbens
nucleus, caudate nucleus, pallidum and putamen is displayed in Fig. 2.
The remaining structures amygdala, hippocampus and thalamus are
shown in Fig. 3. The displacements shown in the ﬁgures are all
signiﬁcant at the 99% signiﬁcance level, with the color coding of the
amount of displacements in millimeters. All displacements were
inwards, representing atrophy. No signiﬁcant areas of hypertrophy
were observed.
Fig. 2. Shape analysis of accumbens, caudate, pallidum and putamen in premanifest and manifest HD. On the left a T1 weighted image with one sided location of the structure
analyzed. Group comparison of shape changes between the premanifest and control group on the second and third image. Left and right are separately displayed, and different views
are provided. The fourth and ﬁfth images display the control group versus themanifest HD group. The color bar on the right indicates the signiﬁcant displacement in mm, white/gray
indicates no signiﬁcant displacement, while red indicates a displacement of 1.5 mm or higher.
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were localized at the caudal side,most prominently seen in themanifest
stage. In the premanifest stage a displacement is seen in the right
accumbens nucleus. The caudate nucleus showed displacements in boththe premanifest and manifest HD group. A generalized displacement is
seen across thewhole caudate nucleus,most signiﬁcantly in the body on
the medial side. In premanifest HD signiﬁcant displacement is seen in
some areas more towards the tail. The pallidum showed a diffuse
Fig. 3. Shape analysis of amygdala, hippocampus and thalamus in premanifest and manifest HD. On the left a T1 weighted image with one sided location of the structure analyzed.
Group comparison of shape changes between the premanifest and control group on the second and third image. Left and right are separately displayed, and different views are
provided. The fourth and ﬁfth images display the control group versus the manifest HD group. The color bar on the right indicates the signiﬁcant displacement in mm, white/gray
indicates no signiﬁcant displacement, while red indicates a displacement of 1.5 mm or higher.
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displaying themost extensive displacements. Displacement is also seen
in this part of the dorsal pallidum in the premanifest HD group. The
putamen showeddisplacement over the entire structure in themanifest
stage, small patches were found in the premanifest stage on the medial
side of the left putamen.
For the amygdala the shape changeswere seen in themanifest stage,
speciﬁcally on the cranial side. No displacements were seen in the
premanifest group. The hippocampus showed patchy displacement
areas at the ventral as well as the dorsal part, this displacement being
limited to the manifest group only. Finally the thalamus showed some
patchy displacements on the ventro-medial, and ventro-lateral side of
the structure, but no real displacement areas could be found in the
premanifest group.
The additional analysis within the premanifest group shows
signiﬁcant results in portions of the caudate nucleus, pallidum and
putamen for the premanifest B group and hardly any signiﬁcant
results in premanifest A group (Figs. 4 and 5). In general this seems to
point out more pronounced shape changes closer to disease onset.4. Discussion
The main focus of this study was to investigate shape changes as a
potentially sensitive measure to quantify pathologic changes in
subcortical nuclei in HD, and in this way provide us with understand-
ing of the atrophy patterns. The atrophy patterns acquired show
localized changes in almost all structures in manifest HD, with a
limited result in premanifest HD, most pronounced closer to predicted
disease onset. Our analysis provides potential speciﬁc target areas for
disease tracking measures, although longitudinal conﬁrmation is
needed.
Localized in vivo shape analysis is a relatively new analysis
technique, not previously implemented in HD research. The potential
scope for application of this analysis is evident as several studies
demonstrated atrophy of the basal ganglia. Overall volume estimates
may not capture the highly localized changes in these subcortical gray
matter structures as these may not have a signiﬁcant impact on
overall volume. Shape analysis may bridge this gap. We emphasize
that the shape analysis approach can be used in all stages of the
Fig. 4. Shape analysis of accumbens nucleus, caudate nucleus, pallidum and putamen in the premanifest groups A and B. Group comparisons of shape changes between the
premanifest far from expected onset (A) and close to expected onset (B) versus control group are shown. Left and right are separately displayed, and different views are provided.
The color bar on the right indicates the signiﬁcant displacement in mm, white/gray indicates no signiﬁcant displacement, while red indicates a displacement of 1.5 mm or higher.
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post-mortem stage. Post-mortem neuron counts imply that the parts
where the most signiﬁcant losses of neurons are seen in very
advanced stages of HD, are also the areas where the shape or volume
change would occur ﬁrst. The pathologic studies available seem to
point towards neuronal changes in speciﬁc portions of the caudate
nucleus, namely the earliest changes are seen in the medial
paraventricular portions of the caudate nucleus and in the tail of the
caudate nucleus [5], which are also the areas seen in our shape
analysis. According to Vonsattel et al. the neuropathological changes
are seen along the antero-posterior, lateral-medial and ventro-dorsalaxis. Also the dorsal part of the putamen, along the dorsal-ventral axis,
has been reported to show the most signiﬁcant neuronal loss [5,6], in
our study the whole putamen seems affected and no speciﬁc
conclusions on pattern can be drawn from this cross sectional
analysis.
Our ﬁndings are in concurrence with the in vivo ﬁndings of
Kassubek et al., who used a VBM approach describing regional striatal
changes corresponding to the dorso-ventral gradient of neuronal loss
described in neuropathological studies [22]. Furthermore, regarding
the thalamus, Kassubek et al. found thalamic subnuclei projecting to
prefrontal areas (dorso-medial subnucleus) and connections to the
Fig. 5. Shape analysis of amygdala, hippocampus and thalamus in the premanifest groups A and B. Group comparisons of shape changes between the premanifest far from expected
onset (A) and close to expected onset (B) versus control group are shown. Left and right are separately displayed, and different views are provided. The color bar on the right
indicates the signiﬁcant displacement in mm, white/gray indicates no signiﬁcant displacement, whilst red indicates a displacement of 1.5 mm or higher.
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complex) to display volume loss [23]. In our study the thalamus
shows patchy displacements in predominantly ventral-medial and
ventral-lateral areas. Although a VBM approach is methodologically
very different from our approach, both give indications on local
changes, and more importantly, the ﬁndings do seem to point to the
same general areas.
The volume analysis in our cohort is in accordance with the
literature [1,2,4,24]. Possibly, shape analysis is sensitive in detecting
some changes that volumetric analysis could not pick up. The
pallidum does show some regions being affected in the premanifest
group, yet no signiﬁcant result in overall volume difference could be
detected. It must be noted that there is a decline in volume detectable
when the left and right pallidum are combined and the premanifest
group is split into two groups according to the predicted years to
onset (data not shown). In contrast, in the premanifest group the
accumbens nucleus, caudate nucleus and putamen show only minor
regional shape changes, alongside their overall volume change,
resulting in the conclusion that a more overall volume decrease is
observed in these speciﬁc structures, rather than any speciﬁc regional
change only. However, in manifest HD the shape differences provides
speciﬁc knowledge about the location of the most signiﬁcant neuron
losses, and gives insight into the non-uniform pattern of atrophy ofthe subcortical gray matter structures. It might be that these speciﬁc
areas could be targeted for sensitive assessment of pathological
change, possibly correlating to disease onset. Perhaps the body of the
caudate nucleus is in respect the most promising candidate as this is
already demonstrated in the premanifest close to disease onset.
As this regional shape analysis approach brings new insights as to
where speciﬁcally these neurons are lost, it is possible to extend this
in vivo knowledge to known anatomical regions within these
structures. For example, the hippocampus anatomy is complex with
multiple distinct functional substructures [25]. Neuropathologic
reports on speciﬁc regions of the hippocampus being involved, such
as the CA1 region in the R2/6 HD mouse model [26], could be
supported by this type of in vivo analysis. This is also true for the
thalamus, whose anatomy is known to be subdivided into several
substructures. Our analysis shows the medial side to be affected,
which could correspond to the mediodorsal part of the thalamus.
Interestingly, Heinsen et al. reported that this part of the thalamus is
speciﬁcally affected in HD [27]. This part of the thalamus receives
input from the prefrontal cortex and the limbic system and in turn
relays them to the prefrontal association cortex. As a result, it plays a
crucial role in cognitive functions such as attention, planning,
organization, multi-tasking and memory which are known to be
impaired in HD [28]. Haber et al. reviews all cortico-basal ganglia-
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pathways one might argue that the regions found in our study
correlate to the orbital frontal cortex and the anterior cingulate cortex
(ventromedial striatum) and the (pre-)motor cortex (ventral anterior
and ventral lateral nuclei) and to circuits between thalamus and basal
ganglia in general as the mediodorsal part of the thalamus receives
the bulk of the basal ganglia output [29].
More speciﬁc pathways on striatal–cortical connections are
described by Lehericy et al. [30]. Extending this knowledge Draganski
et al. demonstrated in healthy subjects in vivo the coexistence of
clearly segregated and also overlapping connections from cortical
sites to basal ganglia subregions [31]. They found that the basal
ganglia are connected in a rostrocaudal gradient of prefrontal
connections in addition to projections to sensorimotor and parietal
cortical areas. Using this knowledge we can extract from our own
results the most severely affected subregions of the basal ganglia and
their associated cortical projections. One example is the severe shape
change in the body of the caudate nucleus which is, according to the
connections described by Draganski, strongly connected to the
dorsolateral prefrontal cortex [31]. This seems to be consistent with
the above described thalamic connections of the prefrontal cortex
which seem to be affected in HD. Another example is the dorsal part of
the pallidum which has strong connections to the motor cortex,
known to be affected in HD [1,31,32]. In this way the locally found
shape changes in subcortical nuclei can be used to extend knowledge
on affected pathways.
However, some caution must be taken not to over interpret these
results, as the outer surface of a structure does not necessarily mean
that neurons are lost within one small speciﬁc subnuclei, as the outer
surface cannot give information about remodeling within one large
structure or the speciﬁc neuronal cell changes, although it does give
important clues as such.
A limitation of our study could be the usage of a relatively new
software package from FSL for segmentation, which hasn't speciﬁcally
been validated in HD. Visual inspection, however, did not reveal any
signiﬁcant mismatches. The method applied gives structure segmen-
tation on an individual basis and can therefore be used to compare
groups. In contrast to this limitation clear several reasons exist in
favor of using FIRST; ﬁrst of all, compared tomanual segmentation the
automated segmentation uses voxel intensity in contrast to the
sometimes difﬁcult visual contrast differences, reducing a rater
dependent bias. Secondly this automated technique is suitable for
implantation on large datasets, whereasmanual segmentation is labor
intensive. Other techniques such as VBM, although proven to
adequately compare groups, is prone to registration artifacts in the
deep graymatter andmay not be suitable for analysis of the pattern of
atrophy in an individual subject [7,33].
Another limitation of this study is apparent in applying a statistical
paradigm not speciﬁcally set for detecting changes in the premanifest
group, where changes are relatively small. When less statistical
scrutiny would be applied larger regions may show displacement, yet
these standards were set before the analysis was performed and did
not interfere with achieving the goal of the study, namely ﬁnding
speciﬁc regional shape changes. Another limitation could also be the
fact that our premanifest group is quite heterogeneous, in regards to
the disease burden which has a substantial range. This disease burden
score can be calculated by: (CAG repeat length — 35.5)×Age, and
correlates well with striatal damage and expected age of onset [9].
This heterogeneity within the premanifest group has been addressed
by performing an additional analysis within the premanifest group,
showing the relationship of shape changes with disease onset. A ﬁnal
limitation is the cross sectional design, which is unsuited to prove the
biomarker quality of localized shape changes and longitudinal follow
up should be performed.
In conclusion, shape analysis provides new insights in patterns of
atrophy in Huntington's disease. Speciﬁc parts of the subcortical graymatter structures are demonstrated to show major shape changes
besides an overall volume change. This study assesses these
differences in vivo and ﬁnds support in known pathologic ﬁndings
in advanced HD. These localized areas provides not only additional
knowledge in localized intrastructural atrophy patterns, but can also
potentially serve as speciﬁc target areas for disease tracking.
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